A cancer-causing protein long thought to be resistant to medication could soon be the target of new drugs, thanks to the work ...

RAS is the most frequently mutated oncogene in cancer, with KRAS mutations occurring in nearly one-quarter of all human cancers. RAS mutations impair the ability of RAS to convert from its active ...

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) to target the active or ON-state of multiple forms of RAS mutations.

These inhibitors use a different mechanism of action than most other KRAS inhibitors (including that in the previous study) ...

The genetic makeup of his tumor showed a specific gene mutation. "The gene can have a ... "These are the so-called RAS inhibitors." Research indicates that RAS inhibitors target a specific protein ...

SAN DIEGO, CA, USA & BERLIN, Germany I April 03, 2025 I Vividion Therapeutics, Inc. (Vividion) today announced that the first patient has been dosed in a ...

RAS-F3 is a small molecule RAS oncogene protein-protein inhibitor for blocking RAS mutations that lead to tumor formation, especially in pancreatic, colorectal and lung cancers. STARS is a DNA/RNA ...

Full abstract details including title and text are currently available to registrants via the AACR online itinerary planner. A copy of the presentation will be available in the Posters and ...

VVD-159642, Vividion's fourth clinical-stage program stemming from its chemoproteomics discovery platform, is designed to improve patient outcomes by inhibiting RAS-PI3Ka, a key signaling pathway ...